In a landmark development for global pandemic preparedness, the University of Oxford has initiated the world’s first Phase II clinical trial for a Nipah virus vaccine candidate. The trial, launched in Bangladesh—a region plagued by recurrent outbreaks—represents a critical advancement in combating one of the world’s deadliest pathogens, for which no approved vaccines or treatments currently exist.
The study involves 306 healthy adult participants aged 18-55 and is being conducted through a strategic partnership between Oxford’s Pandemic Sciences Institute, the International Centre for Diarrhoeal Disease Research, Bangladesh (ICDDR,B), and the Coalition for Epidemic Preparedness Innovations (CEPI), which is providing primary funding. The research aims to evaluate both the safety profile and immune response generated by the ChAdOx1 NipahB vaccine.
Professor Sarah Gilbert, a leading vaccinologist at Oxford, emphasized the trial’s significance: “This initiative in Bangladesh marks a pivotal advancement in our efforts to develop countermeasures against Nipah virus, a formidable health threat that continues to claim lives during periodic outbreaks.”
Professor Brian Angus, Chief Investigator at the Oxford Vaccine Group, highlighted the importance of conducting trials in affected regions: “Initiating Phase II trials in countries experiencing regular Nipah outbreaks ensures that vaccine development remains both effective and contextually relevant to those most vulnerable.”
Dr. Kent Kester, CEPI’s Executive Director of Vaccine Research, noted that Oxford’s candidate represents the most progressed vaccine initiative against the highly lethal Nipah virus, calling the trial “the culmination of years of cutting-edge research and international scientific cooperation.”
The Serum Institute of India, the world’s largest vaccine manufacturer, produced the trial vaccines in collaboration with CEPI. Dr. K Zaman, Senior Scientist at ICDDR,B and Principal Investigator in Bangladesh, emphasized that hosting this trial aligns with their two decades of Nipah surveillance and research, representing a natural progression of their scientific commitment to global health security.